⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Simaya.ai and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Simaya.ai
↗Nir Israel, Israel
Simaya.ai is a biotechnology-focused AI company that develops causal, mechanistic models to improve clinical trial outcomes. Unlike traditional correlational models, Simaya's platform encodes biological cause-and-effect mechanisms to predict individual patient responses, toxicity risks, and optimal dosages.
The company's technology is designed to assist R&D teams in de-risking clinical programs by refining enrollment criteria and supporting dose justification before trials begin. By moving beyond population averages to patient-level, inspectable predictions, Simaya aims to reduce trial failures and enhance the precision of drug development.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:
Industry:Digital Health
Sub-Industry:AI-driven Drug Development / Clinical Trial Optimization
SIZE & FINANCIALS
Employees:1-50
Founded:2026
Ownership:private
Status:operating
PIPELINE
Stage:Discovery
Lead Drug Stage:N/A (Technology Platform)
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
Competitors:CytoReason, Adaptive Biotechnologies
LINKS
Website:simaya.ai
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Simaya.ai. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.